+

WO2001074810A3 - Procede d'utilisation de 2-aryloxyalkylaminobenzoxazoles et de 2-aryloxyalkylaminobenzothiazoles comme antagonistes vis-a-vis du recepteur h3 - Google Patents

Procede d'utilisation de 2-aryloxyalkylaminobenzoxazoles et de 2-aryloxyalkylaminobenzothiazoles comme antagonistes vis-a-vis du recepteur h3 Download PDF

Info

Publication number
WO2001074810A3
WO2001074810A3 PCT/US2001/010050 US0110050W WO0174810A3 WO 2001074810 A3 WO2001074810 A3 WO 2001074810A3 US 0110050 W US0110050 W US 0110050W WO 0174810 A3 WO0174810 A3 WO 0174810A3
Authority
WO
WIPO (PCT)
Prior art keywords
aryloxyalkylaminobenzoxazoles
aryloxyalkylaminobenzothiazoles
antagonists
pharmaceutically
derivatives
Prior art date
Application number
PCT/US2001/010050
Other languages
English (en)
Other versions
WO2001074810A2 (fr
Inventor
Nicholas I Carruthers
Xiaobing Li
Timothy W Lovenberg
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Priority to AU2001251083A priority Critical patent/AU2001251083A1/en
Publication of WO2001074810A2 publication Critical patent/WO2001074810A2/fr
Publication of WO2001074810A3 publication Critical patent/WO2001074810A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne des procédés relatifs à l'utilisation d'imidazopyridines à substitution aryle en 2 ou en 3 pharmaceutiquement actives, y compris leurs dérivés.
PCT/US2001/010050 2000-03-31 2001-03-29 Procede d'utilisation de 2-aryloxyalkylaminobenzoxazoles et de 2-aryloxyalkylaminobenzothiazoles comme antagonistes vis-a-vis du recepteur h3 WO2001074810A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001251083A AU2001251083A1 (en) 2000-03-31 2001-03-29 Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19407100P 2000-03-31 2000-03-31
US60/194,071 2000-03-31
US27229101P 2001-02-28 2001-02-28
US60/272,291 2001-02-28

Publications (2)

Publication Number Publication Date
WO2001074810A2 WO2001074810A2 (fr) 2001-10-11
WO2001074810A3 true WO2001074810A3 (fr) 2002-04-04

Family

ID=26889670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010050 WO2001074810A2 (fr) 2000-03-31 2001-03-29 Procede d'utilisation de 2-aryloxyalkylaminobenzoxazoles et de 2-aryloxyalkylaminobenzothiazoles comme antagonistes vis-a-vis du recepteur h3

Country Status (3)

Country Link
US (1) US6436939B2 (fr)
AU (1) AU2001251083A1 (fr)
WO (1) WO2001074810A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
WO2003024928A2 (fr) 2001-09-14 2003-03-27 Novo Nordisk A/S Nouveau derives d'aminoazetidine, d'aminopyrrolidine et d'aminopiperidine
US7101898B2 (en) 2002-02-01 2006-09-05 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
US6906060B2 (en) 2002-06-06 2005-06-14 Novo Nordisk A/S Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines
SE0202429D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
PT1651615E (pt) 2003-07-29 2010-04-29 High Point Pharmaceuticals Llc Piridazinil-piperazinas e sua utilização como ligandos de receptores h3 de histamina
EP1866293A1 (fr) * 2005-03-31 2007-12-19 UCB Pharma, S.A. Composes comprenant un groupe fonctionnel d'oxazole ou de thiazole, processus de fabrication et leur utilisation
WO2007003604A2 (fr) 2005-07-04 2007-01-11 Novo Nordisk A/S Medicaments
CA2645581A1 (fr) 2006-03-28 2007-10-04 High Point Pharmaceuticals, Llc Benzothiazoles presentant une activite sur le recepteur h3 de l'histamine
JP2009537596A (ja) 2006-05-23 2009-10-29 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ６−（４−シクロプロピルピペリジン−１−イル）−２’−メチル−［３，４’］−ビピリジン及びその医薬としての使用
CN101460487A (zh) 2006-05-29 2009-06-17 高点制药有限责任公司 3-(1，3-苯并间二氧杂环戊烯- 5-基)-6-(4-环丙基哌嗪-1-基)-哒嗪、其盐和溶剂合物及其作为组胺h3受体拮抗剂的用途
LT2799427T (lt) 2006-07-05 2018-11-26 Fibrotech Therapeutics Pty Ltd Terapiniai junginiai
EP2049548A1 (fr) * 2006-07-27 2009-04-22 UCB Pharma, S.A. Oxazoles et thiazoles fusionnés en tant que ligands du récepteur histamine h3
BRPI0810063A2 (pt) 2007-04-20 2014-10-14 Acucela Inc Composto, composição farmacêutica, e, métodos para modular fluxo de cromóforo em um ciclo retinóide, para tratar uma doença ou distúrbio oftálmico em um indivíduo, para inibir adaptação ao escuro em uma célula fotorreceptora de bastão da retina, para inibir regeneração de rodopsina em uma célula fotoreceptora de bastão da retina, para reduzir isquemia em um olho de um indivíduo, para inibir neovascularização na retina de um olho de um indivíduo, e para inibir degeneração de uma célula da retina em uma retina
EP2014656A3 (fr) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC Nouveaux antagonistes d'hétéocycliques h3
TW200918101A (en) * 2007-10-26 2009-05-01 Nihon Mediphysics Co Ltd Novel compound having affinity for amyloid
JP5904944B2 (ja) 2009-10-22 2016-04-20 フィブロテック セラピューティクス プロプライエタリー リミテッド 縮合環類似体の抗線維症剤
WO2013151982A1 (fr) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés
EP3577103A1 (fr) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd. Composés anti-fibrotiques
CN114591264A (zh) * 2020-12-04 2022-06-07 湖南超亟检测技术有限责任公司 一种指示pH值的荧光探针及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268956A2 (fr) * 1986-11-13 1988-06-01 Eisai Co., Ltd. Dérivés de pyridine, leurs compositions pharmaceutiques, leur utilisation pour la fabrication de médicaments ayant une valeur thérapeutique ou préventive, et un procédé pour leur préparation
US4861897A (en) * 1987-06-22 1989-08-29 Ortho Pharmaceutical Corporation 2-Aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles
US5352707A (en) * 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
WO1997043271A1 (fr) * 1996-05-10 1997-11-20 Janssen Pharmaceutica N.V. Derives de l'alkylaminobenzothiazole et alkylaminobenzoxazole
WO1999032115A1 (fr) * 1997-12-19 1999-07-01 Advanced Research And Technology Institute, Inc. Modulateurs des recepteurs de la ryanodine contenant des 2-(aryl)-4,7-dioxobenzothiazoles et leurs analogues
EP0978512A1 (fr) * 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy- (ou arylthio)alkylamines comme antagonistes du recepteur H3 et leur application thérapeutique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727145A (en) 1986-09-22 1988-02-23 Ortho Pharmaceutical Corporation 2- Or 3- aryl substituted imidazo [1,2-a]pyridines
US4880824A (en) 1987-09-21 1989-11-14 Ortho Pharmaceutical Corporation Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers
DE19936309A1 (de) 1999-08-02 2001-02-15 Rohde & Schwarz System zum gemeinsamen Betreiben von auf verschiedene Wellenformen einstellbaren digital arbeitenden Funkgeräten

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268956A2 (fr) * 1986-11-13 1988-06-01 Eisai Co., Ltd. Dérivés de pyridine, leurs compositions pharmaceutiques, leur utilisation pour la fabrication de médicaments ayant une valeur thérapeutique ou préventive, et un procédé pour leur préparation
US4861897A (en) * 1987-06-22 1989-08-29 Ortho Pharmaceutical Corporation 2-Aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles
US5352707A (en) * 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
WO1997043271A1 (fr) * 1996-05-10 1997-11-20 Janssen Pharmaceutica N.V. Derives de l'alkylaminobenzothiazole et alkylaminobenzoxazole
WO1999032115A1 (fr) * 1997-12-19 1999-07-01 Advanced Research And Technology Institute, Inc. Modulateurs des recepteurs de la ryanodine contenant des 2-(aryl)-4,7-dioxobenzothiazoles et leurs analogues
EP0978512A1 (fr) * 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy- (ou arylthio)alkylamines comme antagonistes du recepteur H3 et leur application thérapeutique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARCHIV DE PHARMAZIE, vol. 332, no. 11, November 1999 (1999-11-01), pages 389 - 398 *
C. ROBIN GANELLIN ET AL.: "Synthesis of potent Non-imidazole Histamine H3-Receptor Antagonists", ARCH.PHARM. PHARM. MED. CHEM., vol. 331, 1998, Weinheim, pages 395 - 404, XP002123596 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; WALCZYNSKI KRZYSZTOF ET AL.: "Non-imidatole histamine H3 ligands, part 2: New 2-substituted benzothiazoles as histamine H3 antagonists", XP002185781 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; WALCZYNSKI KRZYSZTOF ET AL.: "Non-imidazole histamine H3 ligands. Part I. Synthesis of 2-(1-Piperazinyl)- and 2-(hexahydro-1H-1,4-diazepin-1-yl)benzothiazole derivatives as H3-antagonists with H1 blocking activities.", XP002185780 *
FARMACO, vol. 54, no. 10, 30 October 1999 (1999-10-30), pages 684 - 694 *

Also Published As

Publication number Publication date
AU2001251083A1 (en) 2001-10-15
WO2001074810A2 (fr) 2001-10-11
US20010044439A1 (en) 2001-11-22
US6436939B2 (en) 2002-08-20

Similar Documents

Publication Publication Date Title
WO2001074810A3 (fr) Procede d'utilisation de 2-aryloxyalkylaminobenzoxazoles et de 2-aryloxyalkylaminobenzothiazoles comme antagonistes vis-a-vis du recepteur h3
WO2001074813A3 (fr) METHODE D'UTILISATION D'IMIDAZO[1,2-a] PYRIDINES SUBSTITUES PAR 2- OU 3-ARYLE COMME ANTAGONISTES DE H¿3?
WO2001074815A3 (fr) Imidazopyridines phenyle-substituees
WO2003045840A3 (fr) Materiaux mesoporeux et procedes de fabrication
WO2003035617A3 (fr) Derives de l'uk-2a
WO2003048081A3 (fr) Glycinamides en tant qu'inhibiteurs du facteur xa
AU2001275239A1 (en) Real-time method for maintaining formation stability
AU2002338336A1 (en) Epothilone derivatives and methods for making and using the same
AU2001240546A1 (en) Method for the preparation of hydrogenated hydrocarbons
WO2003020700A3 (fr) Derives d'indeno[1,2-c]isoquinoleine substitutee et procedes d'utilisation de ces composes
WO2001074773A3 (fr) Indoles et indazoles substitues par phenyle
AP2004002981A0 (en) Method for the preparation of hexahydro-furo [2,3-B]furan-3-o1.
MXPA02008402A (es) Derivados de quinolina como antagonistas alfa-2.
EP1205189A3 (fr) Compositions pharmaceutiques contenant des agonistes des prostaglandines et des inhibiteurs de HMG-CoA réductase pour une stimulation de la croissance osseuse
WO2002024685A8 (fr) Derives de l'indole et leur utilisation en tant qu'agents antifongiques et/ou antiparasitaires
AU2002218075A1 (en) Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them
WO2002024695A3 (fr) Octahydro-indolizine et quinolizine et hexahydro-pyrrolizine
ZA200309514B (en) Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives.
AU2002226356A1 (en) Quinoline derivatives as nk-3 antagonists
IT1313592B1 (it) Derivati di 1h-pirido 3,4-b indol-1-one.
AU2001258718A1 (en) An improved process for the preparation of quinolone derivatives
AU2001228478A1 (en) Method for the simplified production of (3-chloro-4-fluoro-phenyl)-7-(3-morpholino-4-yl-propoxy)-6-nitro-quinazoline-4-yl)-amine or (3-chloro-4-fluoro-phenyl)-(7-(3-morpholino-4-yl-propoxy)-6-amino-quinazoline-4-yl)-amine.
AU2002227952A1 (en) Klainetin and derivatives thereof, method for their production and the use of the same
WO2003099783A3 (fr) Composes de tropane
AU2795202A (en) Klainetin and derivatives thereof, method for their production and the use of the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载